{"protocolSection": {"identificationModule": {"nctId": "NCT00707031", "orgStudyIdInfo": {"id": "EFC6019"}, "secondaryIdInfos": [{"id": "2007-005883-28", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "officialTitle": "A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin", "acronym": "GETGOAL-X"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-06"}, "primaryCompletionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-26", "studyFirstSubmitQcDate": "2008-06-26", "studyFirstPostDateStruct": {"date": "2008-06-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-08-18", "resultsFirstSubmitQcDate": "2016-08-18", "resultsFirstPostDateStruct": {"date": "2016-10-11", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-02-01", "dispFirstSubmitQcDate": "2012-02-01", "dispFirstPostDateStruct": {"date": "2012-02-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-20", "lastUpdatePostDateStruct": {"date": "2016-12-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta\u00ae), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide in comparison to exenatide (Byetta\u00ae), as an add-on treatment to metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than 7 percent (%) or HbA1c less than or equal to (\\<=) 6.5%, fasting plasma glucose (FPG), body weight; to evaluate safety, tolerability and to assess the impact of gastrointestinal tolerance on quality of life (QoL) (patient assessment of upper gastrointestinal disorders - quality of life \\[PAGI-QOL\\]).", "detailedDescription": "Patients who complete the 24-week main open-label treatment would undergo a variable open-label extension treatment, which ends for all patients at approximately the scheduled date of Week 76 visit (Visit 24) for the last randomized patient."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["hyperglycemia, GLP-1, metformin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 639, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lixisenatide", "type": "EXPERIMENTAL", "description": "2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.", "interventionNames": ["Drug: Lixisenatide (AVE0010)", "Device: Pen auto-injector", "Drug: Metformin"]}, {"label": "Exenatide", "type": "ACTIVE_COMPARATOR", "description": "1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.", "interventionNames": ["Drug: Exenatide", "Device: Prefilled pen injector", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Lixisenatide (AVE0010)", "description": "Self administered by subcutaneous injections once daily within the hour preceding breakfast.", "armGroupLabels": ["Lixisenatide"]}, {"type": "DEVICE", "name": "Pen auto-injector", "armGroupLabels": ["Lixisenatide"], "otherNames": ["OptiClik\u00ae"]}, {"type": "DRUG", "name": "Exenatide", "description": "Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.", "armGroupLabels": ["Exenatide"], "otherNames": ["Byetta\u00ae"]}, {"type": "DEVICE", "name": "Prefilled pen injector", "armGroupLabels": ["Exenatide"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.", "armGroupLabels": ["Exenatide", "Lixisenatide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute Change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period", "description": "Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\> 8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline up to Week 24"}], "otherOutcomes": [{"measure": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from hypoglycemia in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "timeFrame": "First dose of study drug up to 3 days after the last dose administration, for up to 116 weeks"}, {"measure": "Quality of Life: Change From Baseline in Patient's Satisfaction to Treatment (PAGI-QOL) at Week 24", "description": "PAGI-QOL: a 30-item self-administered questionnaire to measure health related QOL of patients with upper gastrointestinal disorders during past 2 weeks. Consists of 5 sub-scales. Each item rated on a 0-5 point Likert scale (0 \\[none of the time\\] to 5 \\[all the time\\]). Sub-scale score calculated by dividing sum of all items of subscale by number of items in the sub-scale. Total score calculated by taking mean of sub-scale scores. Sub-scale score and total score ranges from 0=none of the time (lowest score) to 5=all of the time (highest score) with lower scores indicating better QOL. The on-treatment period for this variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 gram per day for at least 3 months prior to screening visit\n\nExclusion Criteria:\n\n* HbA1c less than (\\<) 7% or greater than (\\>) 10% at screening\n* At the time of screening age \\< legal age of majority\n* Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method\n* Type 1 diabetes mellitus\n* Treatment with another antidiabetic pharmacological agent than metformin within the 3 months preceding the screening\n* FPG at screening \\>250 milligram per deciliter (mg/dL) (13.9 millimole per liter \\[mmol/L\\])\n* Body mass index (BMI) less than or equal to (\\<=) 20 kilogram per square meter (kg/m\\^2)\n* Weight change of \\>5 kg during the 3 months preceding the study\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease\n* History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening\n* Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening\n* Within the last 6 months prior to screening, history of myocardial infarction, stroke, or heart failure requiring hospitalization\n* Known history of drug or alcohol abuse within 6 months prior to the time of screening\n* Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period\n* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure or diastolic blood pressure \\>180 millimeter of mercury (mmHg) or \\>95 mmHg, respectively\n* Laboratory findings at the time of screening: aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase: \\>2 times upper limit of the normal (ULN) laboratory range; amylase and/or lipase: \\>3 times ULN; total bilirubin: \\>1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin \\<11 gram/deciliter and/or neutrophils \\<1500 per cubic millimeter (mm\\^3) and/or platelets \\<100 000/ mm\\^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody; and positive serum pregnancy test in females of childbearing potential\n* Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram or vital signs at the time of screening that, in the judgment of the investigator or any sub-investigator, precludes safe completion of the study or constrains efficacy assessment\n* Patients who are considered by the investigator or any sub-investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as attending scheduled visits, being able to do self-injections; likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol; investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)\n* Use of other oral or injectable antidiabetic or hypoglycemic agents than metformin (for example, sulfonylurea, alpha-glucosidase inhibitor, thiazolidinedione, rimonabant, exenatide, dipeptidyl-peptidase-4 inhibitors, insulin) within 3 months prior to the time of screening\n* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening\n* Use of any investigational drug within 3 months prior to study\n* Participation in any previous study with lixisenatide\n* Renal impairment defined with serum creatinine \\>1.4 mg/dL in women and serum creatinine \\>1.5 mg/dL in men\n* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to, gastroparesis and gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening\n* Allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sanofi-Aventis Administrative Office", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Wien", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Santafe de Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Horsholm", "country": "Denmark", "geoPoint": {"lat": 55.88098, "lon": 12.50111}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Helsinki", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Athens", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Milano", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Gouda", "country": "Netherlands", "geoPoint": {"lat": 52.01667, "lon": 4.70833}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Lysaker", "country": "Norway", "geoPoint": {"lat": 59.90994, "lon": 10.63545}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Puerto Rico", "country": "Puerto Rico"}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Bromma", "country": "Sweden", "geoPoint": {"lat": 59.34, "lon": 17.94}}]}, "referencesModule": {"references": [{"pmid": "23698396", "type": "RESULT", "citation": "Rosenstock J, Raccah D, Koranyi L, Maffei L, Boka G, Miossec P, Gerich JE. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013 Oct;36(10):2945-51. doi: 10.2337/dc12-2709. Epub 2013 May 22."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 1243 patients were screened of which 604 were screen failures; main reason for screen failure was glycosylated hemoglobin (HbA1c) values being out of the defined protocol range (greater than or equal to 7% and less than or equal to 10%). A total of 639 patients were randomized.", "recruitmentDetails": "The study was conducted at 122 centers in 18 countries between June 23, 2008 and November 18, 2010. The overall duration of treatment was at least 76 weeks (24 weeks main open-label treatment; variable open-label extension treatment).", "groups": [{"id": "FG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "FG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide: 5 mcg twice daily (BID) subcutaneously for 4 weeks, followed by 10 mcg BID up to the end of treatment."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized", "numSubjects": "320"}, {"groupId": "FG001", "numSubjects": "319"}]}, {"type": "Treated/Safety Population", "achievements": [{"groupId": "FG000", "comment": "All patients who received at least 1 dose, regardless of amount of treatment administered.", "numSubjects": "318"}, {"groupId": "FG001", "numSubjects": "316"}]}, {"type": "Modified Intent-to-Treat Population", "achievements": [{"groupId": "FG000", "comment": "All patients who received at least 1 dose;had baseline;at least 1 post-baseline efficacy assessment.", "numSubjects": "315"}, {"groupId": "FG001", "numSubjects": "315"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "216"}, {"groupId": "FG001", "numSubjects": "220"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "104"}, {"groupId": "FG001", "numSubjects": "99"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Poor Compliance to Protocol", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Familial or Personal Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Serious Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population included all randomized patients who received at least 1 dose of study drug, regardless of the amount of treatment administered. In addition, 5 patients from one site with serious noncompliance issues were excluded from all analysis populations.", "groups": [{"id": "BG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "BG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide: 5 mcg BID subcutaneously for 4 weeks, followed by 10 mcg BID up to the end of treatment."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "318"}, {"groupId": "BG001", "value": "316"}, {"groupId": "BG002", "value": "634"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.3", "spread": "9.2"}, {"groupId": "BG001", "value": "57.6", "spread": "10.7"}, {"groupId": "BG002", "value": "57.4", "spread": "9.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "167"}, {"groupId": "BG001", "value": "129"}, {"groupId": "BG002", "value": "296"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "187"}, {"groupId": "BG002", "value": "338"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Race: Caucasian/White", "categories": [{"measurements": [{"groupId": "BG000", "value": "296"}, {"groupId": "BG001", "value": "292"}, {"groupId": "BG002", "value": "588"}]}]}, {"title": "Race: Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "18"}]}]}, {"title": "Race: Asian/Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "Race: Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Ethnicity: Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "170"}]}]}, {"title": "Ethnicity: Non Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "231"}, {"groupId": "BG001", "value": "233"}, {"groupId": "BG002", "value": "464"}]}]}]}, {"title": "Glycosylated Hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.95", "spread": "0.81"}, {"groupId": "BG001", "value": "7.97", "spread": "0.78"}, {"groupId": "BG002", "value": "7.96", "spread": "0.80"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "millimole per liter (mmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.7", "spread": "2.0"}, {"groupId": "BG001", "value": "9.7", "spread": "2.3"}, {"groupId": "BG002", "value": "9.7", "spread": "2.1"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "94.0", "spread": "19.6"}, {"groupId": "BG001", "value": "96.1", "spread": "22.5"}, {"groupId": "BG002", "value": "95.0", "spread": "21.13"}]}]}]}, {"title": "Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) Total Score", "description": "A 30-item self-administered questionnaire to measure health related quality of life (QOL) of patients with upper gastrointestinal disorders during past 2 weeks; consisted of 5 dimensions (subscales). Each item rated on a 0-5 point Likert scale, where 0=none of the time and 5=all the time. Subscale score was calculated by dividing sum of all items of subscale by number of items in subscale. Total score was calculated by taking the mean of subscale scores. Subscale score and total score range from 0 to 5 with lower scores indicating better quality of life.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.59", "spread": "0.7"}, {"groupId": "BG001", "value": "0.56", "spread": "0.7"}, {"groupId": "BG002", "value": "0.58", "spread": "0.7"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "BMI was calculated by dividing body weight by the height squared.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram per square meter (kg/m^2)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.68", "spread": "6.27"}, {"groupId": "BG001", "value": "33.51", "spread": "6.54"}, {"groupId": "BG002", "value": "33.60", "spread": "6.40"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.78", "spread": "5.54"}, {"groupId": "BG001", "value": "6.75", "spread": "4.87"}, {"groupId": "BG002", "value": "6.76", "spread": "5.21"}]}]}]}, {"title": "Daily Metformin Dose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milligram (mg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2020.20", "spread": "459.41"}, {"groupId": "BG001", "value": "2058.39", "spread": "453.23"}, {"groupId": "BG002", "value": "2039.24", "spread": "456.38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute Change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "297"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.79", "spread": "0.053"}, {"groupId": "OG001", "value": "-0.96", "spread": "0.054"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To detect that upper confidence limit of 2-sided 95% confidence interval for least square (LS) mean difference between the 2 arms do not exceed 0.4% HbA1c, 300 patients per group would provide 96% power assuming a standard deviation of 1.3 and true difference in HbA1c between the 2 arms as 0.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was demonstrated if the upper limit of the 2-sided 95% confidence interval of the difference between lixisenatide and exenatide on mITT population was \\<=0.4%.", "pValueComment": "Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (\\<8.0, \\>=8.0%), BMI (\\<30, \\>=30 kg/m\\^2), country as fixed effects, baseline HbA1c as covariate.", "paramType": "Least squares (LS) mean difference", "paramValue": "0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.033", "ciUpperLimit": "0.297", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}, {"groupId": "OG001", "value": "301"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.22", "spread": "0.116"}, {"groupId": "OG001", "value": "-1.45", "spread": "0.119"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilogram", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "296"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.96", "spread": "0.231"}, {"groupId": "OG001", "value": "-3.98", "spread": "0.232"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "297"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "48.5"}, {"groupId": "OG001", "value": "49.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "297"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.5"}, {"groupId": "OG001", "value": "35.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period", "description": "Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\> 8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "315"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.2"}, {"groupId": "OG001", "value": "3.8"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "2-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "296"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.1"}, {"groupId": "OG001", "value": "31.4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from hypoglycemia in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "populationDescription": "Safety population included all randomized patients who received at least 1 dose of study drug, regardless of the amount of treatment administered.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First dose of study drug up to 3 days after the last dose administration, for up to 116 weeks", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "2-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "316"}]}], "classes": [{"title": "Symptomatic Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "46"}]}]}, {"title": "Severe Symptomatic Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Quality of Life: Change From Baseline in Patient's Satisfaction to Treatment (PAGI-QOL) at Week 24", "description": "PAGI-QOL: a 30-item self-administered questionnaire to measure health related QOL of patients with upper gastrointestinal disorders during past 2 weeks. Consists of 5 sub-scales. Each item rated on a 0-5 point Likert scale (0 \\[none of the time\\] to 5 \\[all the time\\]). Sub-scale score calculated by dividing sum of all items of subscale by number of items in the sub-scale. Total score calculated by taking mean of sub-scale scores. Sub-scale score and total score ranges from 0=none of the time (lowest score) to 5=all of the time (highest score) with lower scores indicating better QOL. The on-treatment period for this variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline PAGI-QOL assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}, {"id": "OG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "302"}, {"groupId": "OG001", "value": "292"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "0.031"}, {"groupId": "OG001", "value": "-0.06", "spread": "0.032"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First dose of study drug up to 3 days after the last dose administration, for up to 116 weeks", "description": "Median exposure to study treatment was 562 and 560 days in lixisenatide and exenatide treatment arms, respectively. The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "eventGroups": [{"id": "EG000", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide.", "seriousNumAffected": 26, "seriousNumAtRisk": 318, "otherNumAffected": 204, "otherNumAtRisk": 318}, {"id": "EG001", "title": "Exenatide", "description": "1-step initiation regimen of exenatide.", "seriousNumAffected": 22, "seriousNumAtRisk": 316, "otherNumAffected": 218, "otherNumAtRisk": 316}], "seriousEvents": [{"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Benign lung neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Gastrointestinal stromal tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Metastatic neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Cognitive disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Facial paresis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 316}]}, {"term": "Subclavian artery stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Prostatitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 316}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 316}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 316}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 49, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 316}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 316}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Hypoglycaemia adverse event is based on investigator reported hypoglycaemia.", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 48, "numAtRisk": 316}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 316}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 316}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 316}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 316}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 316}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 48, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 54, "numAtRisk": 316}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 316}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 91, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 119, "numAtRisk": 316}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 41, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 49, "numAtRisk": 316}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 316}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 316}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 318}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 316}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-us@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077270", "term": "Exenatide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}, {"id": "D000019440", "term": "Anti-Obesity Agents"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M1726", "name": "Exenatide", "asFound": "Bipolar", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M21396", "name": "Anti-Obesity Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnObAg", "name": "Anti-Obesity Agents"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}